

**1080. Antibody Persistence 5 Years After Vaccination at 2 to 10 Years of Age With Quadrivalent MenACWY-CRM Conjugate Vaccine, And Responses To a Booster Vaccination**

Stanley L. Block, MD<sup>1</sup>; Shane Christensen, MD<sup>2</sup>; Bikash Verma, MD<sup>3</sup>; Fang Xie, PhD<sup>3</sup>; Pavitra Keshavan, MD<sup>3</sup>; Peter M Dull, MD<sup>3</sup>; Igor Smolenov, MD<sup>3</sup>; <sup>1</sup>Kentucky Pediatric and Adult Research Center, Bardstow, KY; <sup>2</sup>J. Lewis Research, Inc., Salt Lake City, UT; <sup>3</sup>Novartis Vaccines and Diagnostics, Inc., Cambridge, MA

**Session:** 127. Vaccines: Meningococcal  
 Friday, October 10, 2014: 12:30 PM

**Background.** MenACWY-CRM vaccine was immunogenic in 2–10 year-old children in 1- and 2-dose schedules. As only limited data is available on antibody persistence we assessed bactericidal antibodies 5 years after primary vaccination and response to a booster dose, compared with age-matched vaccine-naïve controls (clinicaltrials.gov NCT01823536).

**Methods.** We enrolled two groups of 7–10 year-olds after 1 (n = 101) or 2 (n = 73) doses of MenACWY-CRM as 2–5 year-olds, and a group of 11–15 year-olds after 1 dose (n = 66) as 6–10 year-olds, with age-matched naïve-controls (n = 120 and 101). We measured serum bactericidal activity with human complement (hSBA) at baseline and 30 days after a booster or first MenACWY-CRM vaccination. Local and systemic reactions and any adverse events were recorded.

**Results.** Five years postvaccination levels of antibodies were still higher than controls in the three vaccinated groups, who displayed anamnestic responses to a booster dose, with 99–100% having hSBA titers ≥ 8 against all four serogroups.

Reactogenicity was similar across groups, 50–67% and 27–36% of children had mild to moderate solicited local and systemic reactions. No vaccine-related SAEs were reported.

**Conclusion.** 5 years after 1- and 2-dose MenACWY-CRM vaccination in 2–10 year-olds, half or more of the children still had persistent antibodies against serogroups C, W and Y with robust responses to a booster dose.

**Disclosures.** S. L. Block, Merck: Investigator, Research grant and Research support S. Christensen, Novartis: Investigator, Research grant B. Verma, Novartis: Employee, Salary F. Xie, Novartis: Employee, Salary P. Keshavan, Novartis: Employee, Salary P. M Dull, Novartis Vaccines : Employee, Salary I. Smolenov, Novartis Vaccines: Employee, Salary

Group	Percentages with hSBA ≥ 8 (95%CI)					
	7–10 years (2 doses)		11–15 years (1 dose)		Naïve Controls	
Time	Pre	Post	Pre	Post	Pre	Post
n/N	13/99	99/99	0/119	88/118	5/101	80/99
A	13 [7, 21]	100 [96, 100]	0 [0, 3]	75 [66, 82]	5 [2, 11]	81 [72, 88]
n/N	32/99	98/98	26/119	96/118	21/100	85/99
C	32 [23, 42]	100 [96, 100]	22 [15, 30]	81 [73, 88]	21 [13, 30]	86 [77, 92]
n/N	73/99	99/99	62/119	110/118	55/101	91/99
W	74 [64, 82]	100 [96, 100]	52 [43, 61]	93 [87, 97]	54 [44, 64]	92 [86, 96]
n/N	48/99	98/98	28/119	101/119	37/101	80/99
Y	48 [38, 59]	100 [95, 100]	24 [16, 32]	85 [77, 91]	37 [27, 47]	81 [72, 88]